P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY

Authors: L. I. Gordon, D. Hoda, L. Shi, S. Guo, F. F. Liu, J. Braverman, R. Dubowy, L. Peng, A. Sehgal

Published: 2022-06-24

DOI: 10.1097/01.hs9.0000849696.81993.90

Source: Full article

---

Abstract

No abstract found.